Theralase Technologies (Theralase Technologies) 3-Year Book Growth Rate : -43.80% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies 3-Year Book Growth Rate?

Theralase Technologies's Book Value per Share for the quarter that ended in Dec. 2023 was $0.01.

During the past 12 months, Theralase Technologies's average Book Value per Share Growth Rate was -42.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was -43.80% per year. During the past 5 years, the average Book Value per Share Growth Rate was -12.40% per year. During the past 10 years, the average Book Value per Share Growth Rate was -9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Theralase Technologies was 194.30% per year. The lowest was -50.90% per year. And the median was 14.60% per year.

Competitive Comparison of Theralase Technologies's 3-Year Book Growth Rate

For the Medical Devices subindustry, Theralase Technologies's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's 3-Year Book Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's 3-Year Book Growth Rate falls into.

Theralase Technologies 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Theralase Technologies (OTCPK:TLTFF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Theralase Technologies 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies (Theralase Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.